Search

Your search keyword '"Amanda, Mocroft"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Amanda, Mocroft" Remove constraint Author: "Amanda, Mocroft" Publisher ovid technologies (wolters kluwer health) Remove constraint Publisher: ovid technologies (wolters kluwer health)
39 results on '"Amanda, Mocroft"'

Search Results

1. Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV

2. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

Catalog

Books, media, physical & digital resources

3. Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV

4. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period

5. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort

6. Contemporary protease inhibitors and cardiovascular risk

7. Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

8. Thrombocytopenia and cancer risk during HIV infection

9. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

10. Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons

11. Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption

12. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements

13. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study

14. Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe

15. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

16. Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen

17. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

18. Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study

19. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre

20. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study

21. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens

22. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

23. Regional survival differences across Europe In HIV-positive people: the EuroSIDA study

24. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy

25. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997

26. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe

27. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor

28. Evaluating the effect of year of seroconversion on HIV progression in cohort studies

29. A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses

30. Survival after a very low (< 5 × 106/l) CD4+ T-cell count in individuals infected with HIV

31. Cross-Sectional Studies in AIDS Pathogenesis

32. Highly active antiretroviral therapy and cervical intraepithelial neoplasia

33. Reduced bone mineral density in HIV-positive individuals

34. Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy

35. Changes in AIDS-Defining Illnesses in a London Clinic, 1987???1998

36. The use of CD4 counts as prognostic markers in HIV infection

37. A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival

38. Impact of Kaposi‚s sarcoma on HIV disease progression